Protara Therapeutics, Inc. (TARA) financial statements and ratios from SEC XBRL: revenue $6.38M (TTM), net margin -900.3%, revenue growth 53.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.38M |
| Net Margin | -900.3% |
| Revenue Growth (YoY) | 53.0% |
| EPS Growth (YoY) | -38.2% |
| FCF Growth (YoY) | 57.4% |
| Price / Book | 1.34 |
| Price / Sales | 31.54 |
| FCF Yield | -35.4% |
| Altman Z-Score | 7.40 (safe) |
| Sector P/E (Healthcare) | 21.7 |
TARA overview · TARA earnings · TARA KPIs · TARA investor relations · TARA ownership · TARA peers · TARA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.